Aernoud Fiolet

181 The efficacy and safety of low-dose colchicine in patients with coronary disease Figure 1: Primary and Secondary End Point Composite of myocardial infarction, stroke, or cardiovascular death (major adverse cardiovascular events) Composite of myocardial infarction, stroke, coronary revascularisation, or cardiovascular death Figure 1. Primary and secondary endpoint. Pooled relative risks and 95% confidence intervals for the composite of myocardial infarction, stroke, or cardiovascular death (upper panel) and for the composite of myocardial infarction, stroke, coronary revascularization, or cardiovascular death (lower panel) in patients treated with colchicine as compared with placebo or no colchicine. CI, confidence interval; GIV, generic inverse variance. The primary and secondary endpoints are summarized in Figure 1 and the Graphical abstract. A total of 578 patients developed a primary endpoint. Overall, colchicine reduced the risk for the primary endpoint of MACE, the composite of myocardial infarction, stroke, or cardiovascular death, by 25% [RR 0.75; 95% confidence interval (CI) 0.61–0.92; P=0.005, with low heterogeneity, I 2 = 23.9%]. For the key secondary endpoint of myocardial infarction, stroke, coronary revascularization, or cardiovascular death, the pooled RR reduction was 33% (RR 0.67; 95% CI 0.55–0.82, P<0.001). Subgroup analysis showed no significant interaction between treatment and acute coronary syndrome or chronic coronary disease for the primary (P=0.279) or the secondary (P=0.620) endpoint